What Is Amylin? How It Differs From GLP-1 Signaling

Amylin is a hormone made by the beta cells of the pancreas, the same cells that make insulin. After a meal, the two are released together. Amylin's job is to help manage what happens next: it slows how quickly food leaves the stomach, damps down the rise in glucagon after eating (which helps limit the liver's release of glucose), and adds to the feeling of being full through signals in the brain. In people with diabetes, amylin release is reduced.

Researchers have built longer-acting versions of amylin, including cagrilintide, and are studying whether this pathway can work alongside GLP-1 medicines.

How is amylin different from GLP-1?

They're separate hormone systems with overlapping effects. GLP-1 is mostly released by cells in the gut and acts on the GLP-1 receptor. Amylin comes from the pancreas and acts on its own set of receptors. Both affect appetite, fullness and post-meal blood sugar, which is why combining them is interesting, but they aren't the same signal.

Is amylin already used in medicine?

Yes, in a narrow way. Pramlintide (Symlin), an amylin analogue, has been FDA-approved since 2005 as an add-on treatment for adults with type 1 or type 2 diabetes who use mealtime insulin. It's injected with meals and carries a boxed warning about severe low blood sugar when used with insulin. It isn't approved for weight management. Cagrilintide is a different, longer-acting molecule designed for once-weekly dosing.

What do the cagrilintide trials show?

The main evidence comes from CagriSema, a weekly injection combining cagrilintide 2.4 mg with semaglutide 2.4 mg. In the peer-reviewed REDEFINE 1 trial (3,417 adults with obesity or overweight without diabetes, 68 weeks), average weight change was −20.4% with the combination versus −3.0% with placebo. The trial also included smaller groups on cagrilintide alone and semaglutide alone. Gastrointestinal side effects were common with the combination (79.6% versus 39.9% on placebo), mostly mild to moderate and temporary.

A combination also has to earn its place against existing options. In a company-reported head-to-head trial (REDEFINE 4), CagriSema did not show it was non-inferior to tirzepatide 15 mg for weight loss. For the full trial picture, see CagriSema explained.

Is this something to try now?

No. As of October 2026, neither cagrilintide nor CagriSema is FDA-approved; Novo Nordisk submitted CagriSema to the FDA in December 2025 and expects a decision in late 2026. Products sold online as cagrilintide or amylin "research peptides" aren't the medicine tested in trials, and their identity, purity and dose can't be verified. Approved GLP-1 medicines each have their own label, and an experimental combination isn't interchangeable with them.

What to watch next

Look for full peer-reviewed results of the newer trials, longer follow-up, side-effect and discontinuation rates, and whether benefits extend to health outcomes beyond weight. Regulatory decisions may vary by country, so always check the date on any status update.

Understanding amylin helps explain one direction obesity research is heading. It doesn't mean every new combination will be better, or right for everyone.